WO1999043361A1 - Derives de glp-2 avec teneur en structures en helices superieure a 25 %, formant des agregats de type micellaire partiellement structures - Google Patents

Derives de glp-2 avec teneur en structures en helices superieure a 25 %, formant des agregats de type micellaire partiellement structures Download PDF

Info

Publication number
WO1999043361A1
WO1999043361A1 PCT/DK1999/000080 DK9900080W WO9943361A1 WO 1999043361 A1 WO1999043361 A1 WO 1999043361A1 DK 9900080 W DK9900080 W DK 9900080W WO 9943361 A1 WO9943361 A1 WO 9943361A1
Authority
WO
WIPO (PCT)
Prior art keywords
glp
pharmaceutical composition
composition according
group
derivative
Prior art date
Application number
PCT/DK1999/000080
Other languages
English (en)
Other versions
WO1999043361A8 (fr
Inventor
Liselotte Bjerre Knudsen
Per Olaf Huusfeldt
Per Franklin Nielsen
Niels C. Kaarsholm
Helle Birk Olsen
Lars Thim
Søren Erik BJØRN
Original Assignee
Novo Nordisk A/S
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk A/S filed Critical Novo Nordisk A/S
Priority to AU27128/99A priority Critical patent/AU2712899A/en
Priority to JP2000533156A priority patent/JP2002504527A/ja
Priority to EP99907325A priority patent/EP1060192A2/fr
Publication of WO1999043361A1 publication Critical patent/WO1999043361A1/fr
Publication of WO1999043361A8 publication Critical patent/WO1999043361A8/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Definitions

  • the present invention relates to a pharmaceutical composition comprising a GLP-2 derivative of improved solubility and/or stability, and to a method for improving the solubility and/or stability of GLP-2 or a fragment or an analogue thereof.
  • Peptides are widely used in medical practice, and since they can be produced by recombinant DNA technology it can be expected that their importance will increase also in the years to come. When native peptides or analogues thereof are used in therapy it is generally found that they have a high clearance. A high clearance of a therapeutic agent is inconvenient in cases where it is desired to maintain a high blood level thereof over a prolonged period of time since repeated administrations will then be necessary.
  • peptides which have a high clearance are: ACTH, corticotropin-releasing factor, angiotensin, calcitonin, insulin, glucagon, glu- cagon-like peptide-1 , glucagon-like peptide-2, insulin-like growth factor-1 , insulin-like growth factor-2, gastric inhibitory peptide, growth hormone-releasing factor, pituitary adenylate cyclase activating peptide, secretin, enterogastrin, somatostatin, somatotropin, somatomedin, parathyroid hormone, thrombopoietin, erythropoietin, hypothalamic releasing factors, prolactin, thyroid stimulating hormones, endorphins, enkephalins, vasopressin, oxytocin, opiods and analogues thereof, superoxide dismutase, interferon, asparaginase, arginase, arginine deamina
  • GLP-2 and other preproglucagon fragments are given La. by Schmidt et al. (Diabetologia 28 704-707 (1985). Little is known about the physical chemical properties of GLP-2 but GLP-2 is expected, like GLP-1 , to be a highly flexible and unstable molecule. GLP-2 and fragments thereof and analogues of GLP-2 and fragments thereof are potentially useful La. in regulation of appetite and in the treatment of small bowel syndrome. However, the high clearance limits the usefulness of these compounds, and thus there still is a need for improvements in this field. We recently found that derivatisation of this relatively small and very flexible molecule resulted in compounds whose plasma profile were highly protracted and still had retained activity (PCT application No. DK97/00360).
  • Preproglucagon from which GLP-2 originates, is synthesized a. in the L-cells in the distal ille- um, in the pancreas and in the brain. Processing of preproglucagon to give GLP-1 and GLP-2 occurs mainly in the L-cells.
  • GLP-2 is a 33 amino acid residue peptide possibly in some tissue expended to 34 amino acid residues.
  • a simple system is used to describe fragments, analogues and derivatives of GLP-2.
  • Lys 20 GLP-2(1-33) designates a fragment of GLP-2 formally derived from GLP-2 by deleting the amino acid residues No. 34 and substituting the naturally occurring amino acid residue in position 20 (Arg) by Lys.
  • Arg 30 Lys 35 (N ⁇ -tetradecanoyl)GLP-2(1-35) designates a derivative of a GLP-2 analogue formally derived from GLP-2 by C-terminal addition of a Lys residue, exchange of the naturally occurring amino acid residue in position 30 (Lys) with an Arg residue and tetradecanoylation of the ⁇ - amino group of the Lys residue in position 35.
  • GLP-2 derivatives that are found to be very protracted.
  • GLP-2 and GLP-2 analogues are molecules to which no defined solution structure can be ascribed
  • CD Circular Dichroism
  • CD can be used to show that the GLP-2 derivatives have a certain partially structured conformation independent of their concentration.
  • an increase in the helix content is seen with increasing concentration, from 10-15% to 30-35% (at 500 ⁇ M concentration) in parallel with peptide self-association.
  • the helix content remains constant above 30% at concentrations of 10 ⁇ M.
  • the aggregated structured conformation is an inherent property of the derivative present in water or dilute aqueous buffer without the need for any additional structure-inducing components.
  • the CD signal is proportional to the average content of ⁇ -helix in the peptides, i.e., a CD value of -1 corresponds to 10% ⁇ - helix content under these conditions.
  • the present invention relates to a pharmaceutical composition
  • a pharmaceutical composition comprising a GLP-2 derivative which has a helix content as measured by CD at 222 nm in H 2 O at 22 ⁇ 2 °C exceeding 25%, preferably in the range of 25% to 50%, at a peptide concentration of about 10 ⁇ M.
  • the size of the partially helical, micelle-like aggregates may be estimated by size-exclusion chromatography.
  • the apparent (critical micelle concentrations) CMC's of the peptides may be estimated from the concentration dependent fluorescence in the presence of appropriate dyes (e.g. Brito, . & Vaz, W. (1986) Anal. Biochem. 152, 250-255).
  • the derivatives have a partially structured micellar-like aggregate conformation in aqueous solutions makes them more soluble and stable in solution as compared to the native peptide.
  • the increased solubility and stability can be seen by comparing the solubility after 9 days of standing for a derivative and normal GLP-2(1-34) in a pharmaceutical formulation, e.g. 5 mM phosphate buffer, pH 6.9 added 0.1 M NaCI.
  • an analogue is used to designate a peptide wherein one or more amino acid residues of the parent peptide have been substituted by another amino acid residue and/or wherein one or more amino acid residues of the parent peptide have been deleted and/or wherein one or more amino acid residues have been added to the parent peptide. Such addition can take place either at the N-terminal end or at the C-terminal end of the parent peptide or both.
  • derivative is used in the present text to designate a peptide in which one or more of the amino acid residues of the parent peptide have been chemically modified, e.g. by alkylati- on, acylation, ester formation or amide formation.
  • GLP-2 derivative is used in the present text to designate a derivative of GLP-2 or an analogue thereof.
  • the parent peptide from which such a derivative is formally derived is in some places referred to as the "GLP-2 moiety" of the derivative.
  • the present invention relates to pharmaceutical composition accor- ding to claim 1 , wherein the concentration of GLP-2 derivative is not less than 0.5 mg/ml, preferably not less than about 5 mg/ml, more preferred not less than about 10 mg/ml and, preferably, not more than about 100 mg/ml.
  • composition of the invention preferably comprises a GLP-2 derivative whe- rein at least one amino acid residue of the parent peptide has a lipophilic substituent attached. More preferred are compositions comprising a GLP-2 derivative having a lipophilic substituent which is attached to any one of the amino acid residues in 20-34, preferably 30-34, most preferred 30.
  • composition according to the invention preferably further comprises one or more of the following substances:
  • an isotonic agent preferably selected from the group consisting of sodium chloride, mannitol and glycerol;
  • a preservative preferably selected from the group consisting of phenol, m-cresol, methyl p- hydroxybenzoate, butyl p-hydroxybenzoate and benzyl alcohol;
  • a buffer preferably selected from the group consisting of sodium acetate, citrate, glycylgly- cine, histidine, 2-phenylethanol and sodium phosphate;
  • the pharmaceutical composition of the invention comprises a GLP- 2 derivative wherein the lipophilic substituent comprises from 4 to 40 carbon atoms, preferably from 8 to 25 carbon atoms.
  • the lipophilic substituent is preferably attached to an amino acid residue in such a way that a carboxyl group of the lipophilic substituent forms an amide bond with an amino group of the amino acid residue, or, the lipophilic substituent is attached to an amino acid residue in such a way that an amino group of the lipophilic substituent forms an amide bond with a carboxyl group of the amino acid residue.
  • composition according to the invention compri- ses a GLP-2 derivative wherein the lipophilic substituent is attached to the parent peptide by means of a spacer.
  • the spacer is preferably, in one embodiment, an unbranched alkane ⁇ , ⁇ -dicarboxylic acid group having from 1 to 7 methylene groups, preferably two methylene groups, which form a bridge between an amino group of the parent peptide and an amino group of the lipophilic sub- stituent.
  • the spacer is preferably, in another embodiment, an amino acid residue except Cys, or a di- peptide such as Gly-Lys or any unbranched alkane ⁇ , ⁇ -aminoacid having from 1 to 7 methylene groups, preferably 2-4 methylene groups, which form a bridge between an amino group of the parent peptide and an amino group of the lipophilic substituent.
  • a di- peptide such as Gly-Lys or any unbranched alkane ⁇ , ⁇ -aminoacid having from 1 to 7 methylene groups, preferably 2-4 methylene groups, which form a bridge between an amino group of the parent peptide and an amino group of the lipophilic substituent.
  • the lipophilic substituent comprises a partially or completely hydro- genated cyclopentanophenathrene skeleton.
  • the lipophilic substituent is a straight-chain or branched alkyl group.
  • the lipophilic substituent is preferably the acyl group of a straight-chain or branched fatty acid, the acyl group more preferably being:
  • CH 3 (CH 2 ) n CO- wherein n is 4 to 38, preferably CH 3 (CH 2 ) 6 CO-, CH 3 (CH 2 ) 8 CO-, CH 3 (CH 2 ) 10 CO-, CH 3 (CH 2 ) 12 CO-, CH 3 (CH 2 ) 14 CO-, CH 3 (CH 2 ) 16 CO-, CH 3 (CH 2 ) 18 CO-, CH 3 (CH 2 ) 20 CO- and CH 3 (CH 2 ) 22 CO-; or
  • an acyl group of a straight-chain or branched alkane ⁇ , ⁇ -dicarboxylic acid or • selected from the group comprising HOOC(CH 2 ) m CO-, wherein m is from 4 to 38, preferably from 4 to 24, more preferred selected from the group comprising HOOC(CH 2 ) 14 CO-, HOOC(CH 2 ) 16 CO-, HOOC(CH 2 ) 18 CO-, HOOC(CH 2 ) 20 CO- and HOOC(CH 2 ) 22 CO-.
  • the lipophilic substituent is a group of the formula CH 3 (CH 2 ) p ((CH 2 ) q COOH)CHNH-CO(CH 2 ) 2 CO-, wherein p and q are integers and p+q is an integer of from 8 to 33, preferably from 12 to 28.
  • the lipophilic substituent is a group of the formula CH 3 (CH 2 ) r CO-NHCH(COOH)(CH 2 ) 2 CO-, wherein r is an integer of from 10 to 24.
  • the lipophilic substituent is a group of the formula CH 3 (CH 2 ) s CO-NHCH((CH 2 ) 2 COOH)CO-, wherein s is an integer of from 8 to 24.
  • the lipophilic substituent is a group of the formula -NHCH(COOH)(CH 2 ) 4 NH-CO(CH 2 ) u CH 3 , wherein u is an integer of from 8 to 18.
  • the lipophilic substituent is a group of the formula -NHCH(COOH)(CH 2 ) 4 NH-COCH((CH 2 ) 2 COOH)NH-CO(CH 2 ) w CH 3 , wherein w is an integer of from 10 to 16.
  • the lipophilic substituent is a group of the formula -NHCH(COOH)(CH 2 ) 4 NH-CO(CH 2 ) 2 CH(COOH)NH-CO(CH 2 ) x CH 3 , wherein x is an integer of from 10 to 16.
  • the lipophilic substituent is a group of the formula -NHCH(COOH)(CH 2 ) 4 NH-CO(CH 2 ) 2 CH(COOH)NH-CO(CH 2 ) y CH 3 , wherein y is zero or an integer of from 1 to 22.
  • the pharmaceutical composition according to the invention comprises a GLP-2 derivative wherein the parent peptide is selected from the group comprising GLP- 2(1-30); GLP-2(1-31); GLP-2(1-32); GLP-2(1-33); GLP-2(1-34) and GLP-2(1-35).
  • the pharmaceutical composition according to the invention comprises a GLP-2 derivative wherein the parent peptide has the following amino acid sequence: X 1 HX 2 DGSFSDEMNTX 3 LDX 4 LAX 5 X 6 DFINWLX 7 X 8 TKITDX 9
  • X 1 is NH 2 , DFPEEVAIVEELGRR, DFPEEVTIVEELGRR, DFPEEVNIVEELRRR, or a fragment thereof, X 2 is Ala or Gly,
  • the pharmaceutical composition according to the invention preferably comprises a GLP-2 deri- vative wherein a total of up to fifteen, preferably up to ten, more preferably up to six, amino a- cid residues have been exchanged with any ⁇ -amino acid residue which can be coded for by the genetic code.
  • the parent peptide is most preferably selected from the group comprising:
  • the pharmaceutical composition of the present invention comprises a GLP-2 derivative which is selected from the group comprising
  • Lys 20 (N ⁇ -tetradecanoyl)GLP-2(1-33);
  • Lys z 30 bis(N ⁇ -tetradecanoyl)GLP-2(1-33);
  • Lys 20 (N ⁇ -tetradecanoyl)Arg 30 GLP-2(1-33);
  • the present invention furthermore relates to a method for improving the solubility and/or stability of GLP-2 or a fragment or an analogue thereof, characterised in that a lipophilic substituent is introduced on any one of the amino acid residues of the parent peptide.
  • the lipophilic substituent is preferably introduced on any one of the amino acid residues in position 20-34, preferably 30-34, most preferred 30.
  • the lipophilic substituent preferably comprises from 4 to 40 carbon atoms, more preferably from 8 to 25 carbon atoms.
  • the lipophilic substituent is the acyl group of a straight-chain or branched fatty acid; preferably selected from the group comprising CH 3 (CH 2 ) n CO-, wherein n is 4 to 38, preferably CH 3 (CH 2 ) 6 CO-, CH 3 (CH 2 ) 8 CO-, CH 3 (CH 2 ) 10 CO-, CH 3 (CH 2 ) 12 CO-, CH 3 (CH 2 ) 14 CO-, CH 3 (CH 2 ) 16 CO-, CH 3 (CH 2 ) 18 CO-, CH 3 (CH 2 ) 20 CO- and CH 3 (CH 2 ) 22 CO-.
  • the GLP-2 parent peptide is preferably GLP-2(1-30); GLP-2(1-31); GLP-2(1-32); GLP-2(1-33); GLP-2(1-34) and GLP-2(1-35).
  • the lipophilic substituent attached to the GLP-2 moiety preferably comprises 4-40 carbon atoms, in particular 8- 25 carbon atoms.
  • the lipophilic substituent may be attached to an amino group of the GLP-2 moiety by means of a carboxyl group of the lipophilic substituent which forms an amide bond with an amino group of the amino acid to which it is attached.
  • the lipophilic substituent may be attached to said amino acid in such a way that an amino group of the lipophilic substituent forms an amide bond with a carboxyl group of the amino acid.
  • the lipophililic substituent may be linked to the GLP-2 moiety via an ester bond.
  • the ester can be formed either by reaction between a carboxyl group of the GLP-2 moiety and a hydroxyl group of the substituent-to-be or by reaction between a hydroxyl group of the GLP-2 moiety and a carboxyl group of the substituent-to-be.
  • the lipophilic substituent can be an alkyl group which is introduced into a primary amino group of the GLP-2 moiety.
  • the lipophilic substituent is attached to the GLP- 2 moiety by means of a spacer in such a way that a carboxyl group of the spacer forms an amide bond with an amino group of the GLP-2 moiety.
  • suitable spacers are suc- cinic acid, Lys, Glu or Asp, or a dipeptide such as Gly-Lys.
  • the spacer is succinic acid, one carboxyl group thereof may form an amide bond with an amino group of the amino acid residue, and the other carboxyl group thereof may form an amide bond with an amino group of the lipophilic substituent.
  • the spacer is Lys, Glu or Asp
  • the carboxyl group thereof may form an amide bond with an amino group of the amino acid residue
  • the amino group thereof may form an amide bond with a carboxyl group of the lipophilic substituent.
  • a further spacer may in some instances be inserted between the ⁇ -amino group of Lys and the lipophilic substituent.
  • such a further spacer is succinic acid which forms an amide bond with the ⁇ -amino group of Lys and with an amino group present in the lipophilic substituent.
  • such a further spacer is Glu or Asp which forms an amide bond with the ⁇ -amino group of Lys and another amide bond with a carboxyl group present in the lipophilic substituent, that is, the lipophilic substituent is a N ⁇ -acylated lysine residue.
  • the lipophilic substituent has a group which can be negatively charged.
  • One preferred group which can be negatively charged is a carboxylic acid group.
  • the parent peptide can be produced by a method which comprises culturing a host cell containing a DNA sequence encoding the peptide and capable of expressing the peptide in a suitable nutrient medium under conditions permitting the expression of the peptide, after which the resulting peptide is recovered from the culture.
  • the medium used to culture the cells may be any conventional medium suitable for growing the host cells, such as minimal or complex media containing appropriate supplements. Suitable media are available from commercial suppliers or may be prepared according to published re- cipes (e.g. in catalogues of the American Type Culture Collection).
  • the peptide produced by the cells may then be recovered from the culture medium by conventional procedures including separating the host cells from the medium by centrifugation or filtration, precipitating the prote- inaceous components of the supernatant or filtrate by means of a salt, e.g. ammonium sulphate, purification by a variety of chromatographic procedures, e.g. ion exchange chromato- graphy, gelfiltration chromatography, affinity chromatography, or the like, dependent on the type of peptide in question.
  • a salt e.g. ammonium sulphate
  • the DNA sequence encoding the parent peptide may suitably be of genomic or cDNA origin, for instance obtained by preparing a genomic or cDNA library and screening for DNA sequen- ces coding for all or part of the peptide by hybridisation using synthetic oligonucleotide probes in accordance with standard techniques (see, for example, Sambrook, J, Fritsch, EF and Ma- niatis, T, Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Laboratory Press, New York, 1989).
  • the DNA sequence encoding the peptide may also be prepared synthetically by established standard methods, e.g.
  • the DNA sequence may also be prepared by polyme- rase chain reaction using specific primers, for instance as described in US 4,683,202 or Saiki et a/., Science 239 (1988), 487 - 491.
  • the DNA sequence may be inserted into any vector which may conveniently be subjected to recombinant DNA procedures, and the choice of vector will often depend on the host cell into which it is to be introduced.
  • the vector may be an autonomously replicating vector, i.e. a vector which exists as an extrachromosomal entity, the replication of which is independent of chromosomal replication, e.g. a plasmid.
  • the vector may be one which, when in- troduced into a host cell, is integrated into the host cell genome and replicated together with the chromosome(s) into which it has been integrated.
  • the vector is preferably an expression vector in which the DNA sequence encoding the peptide is operably linked to additional segments required for transcription of the DNA, such as a pro- moter.
  • the promoter may be any DNA sequence which shows transcriptional activity in the host cell of choice and may be derived from genes encoding proteins either homologous or heterologous to the host cell. Examples of suitable promoters for directing the transcription of the DNA encoding the peptide of the invention in a variety of host cells are well known in the art, cf. for instance Sambrook et a/., supra.
  • the DNA sequence encoding the peptide may also, if necessary, be operably connected to a suitable terminator, polyadenylation signals, transcriptional enhancer sequences, and translati- onal enhancer sequences.
  • the recombinant vector of the invention may further comprise a DNA sequence enabling the vector to replicate in the host cell in question.
  • the vector may also comprise a selectable marker, e.g. a gene the product of which complements a defect in the host cell or one which confers resistance to a drug, e.g. ampicillin, kana- mycin, tetracyclin, chloramphenicol, neomycin, hygromycin or methotrexate.
  • a selectable marker e.g. a gene the product of which complements a defect in the host cell or one which confers resistance to a drug, e.g. ampicillin, kana- mycin, tetracyclin, chloramphenicol, neomycin, hygromycin or methotrexate.
  • a secretory signal sequence (also known as a leader sequence, prepro sequence or pre sequence) may be provided in the recombinant vector.
  • the secretory signal sequence is joined to the DNA sequence encoding the peptide in the correct reading frame.
  • Secretory signal sequ- ences are commonly positioned 5' to the DNA sequence encoding the peptide.
  • the secretory signal sequence may be that normally associated with the peptide or may be from a gene encoding another secreted protein.
  • the host cell into which the DNA sequence or the recombinant vector is introduced may be any cell which is capable of producing the present peptide and includes bacteria, yeast, fungi and higher eukaryotic cells.
  • suitable host cells well known and used in the art are, without limitation, E. coli, Saccharomyces cerevisiae, or mammalian BHK or CHO cell lines.
  • the GLP-2 derivatives of the invention can be prepared by introducing the lipophilic substituent into the parent GLP-2 or GLP-2 analogue using methods known perse, see for example WO 95/07931 , the contents of which is hereby incorporated in its entirety by reference.
  • N ⁇ -acylation of a Lys residue can be carried out by using an activated amide of the acyl group to be introduced as the acylating agent, e.g. the amide with benzot azole.
  • the acylation is carried out in a polar solvent in the presence of a base.
  • compositions containing a GLP-2 derivative according to the present invention may be administered parenterally or orally to patients in need of such a treatment.
  • Parenteral administration may be performed by subcutaneous, intramuscular or intravenous injection by means of a syringe, optionally a pen-like syringe.
  • parenteral administration can be performed by means of an infusion pump.
  • a further option is a composition which may be a powder or a liquid for the administration of the GLP-2 derivative in the form of a nasal or pul- monal spray.
  • the pharmaceutical compositions containing a the GLP-2 derivatives of the invention can also be adapted to transdermal administration, e.g. from a patch, optionally a iontophoretic patch, or transmucosal, e.g. bucal, administration.
  • compositions containing a GLP-2 derivative of the present invention may be prepared by conventional techniques, e.g. as described in Remington's Pharmaceutical Sciences, 1985 or in Remington: The Science and Practice of Pharmacy, 19 th edition, 1995.
  • the injectable compositions of the GLP-2 derivative of the invention can be prepared using the conventional techniques of the pharmaceutical industry which involves dissolving and mixing the ingredients as appropriate to give the desired end product.
  • the GLP-2 derivative is dissolved in an amount of water which is somewhat less than the final volume of the composition to be prepared.
  • An isotonic agent, a preservative and a buffer is added as required and the pH value of the solution is adjusted - if necessary - using an acid, e.g. hydrochloric acid, or a base, e.g. aqueous sodium hydroxide as needed.
  • the volume of the solution is adjusted with water to give the desired concentration of the ingredients.
  • composition for nasal administration of certain peptides may, for example, be prepared as described in European Patent No. 272097 (to Novo Nordisk A/S) or in WO 93/18785.
  • the pharmaceutical compositions containing a GLP-2 derivative is provided in the form of a composition suitable for administration by injection.
  • a composition can either be an injectable solution ready for use or it can be an amount of a solid composition, e.g. a lyophilised product, which has to be dissolved in a solvent before it can be injected.
  • the injectable solution preferably contains not less than about 0.5 mg/ml, preferably not less than about 5 mg/ml, more preferred not less than about 10 mg/ml of the GLP-2 derivative and, preferably, not more than about 100 mg/ml of the GLP-2 derivative.
  • compositions containing a GLP-2 derivative of this invention can be used in the treatment of various diseases, including obesity, small bowel syndrome, Crohn's disease, ileitis, intestinal inflammation, gastric and duodenal ulceration, inflammatory bowel disease (IBD) and intestinal cancer damage therapy.
  • diseases including obesity, small bowel syndrome, Crohn's disease, ileitis, intestinal inflammation, gastric and duodenal ulceration, inflammatory bowel disease (IBD) and intestinal cancer damage therapy.
  • IBD inflammatory bowel disease
  • the particular GLP-2 derivative to be used and the optimal dose level for any patient will depend on the disease to be treated and on a variety of factors including the efficacy of the specific peptide derivative employed, the age, body weight, physical activity, and diet of the patient, on a possible combination with other drugs, and on the severity of the case. It is recommended that the dosage of the GLP-2 derivative of this invention be determined for each individual patient by those skilled in the art.
  • the title compound (0.1 mg, 1.8 %) was isolated, and the product was analysed by PDMS.
  • the m/z value for the protonated molecular ion was found to be 4107.8 ⁇ 3.
  • the resulting molecular weight is thus 4106.8 ⁇ 3 amu (theoretical value 4106 amu).

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Child & Adolescent Psychology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Diabetes (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)

Abstract

Cette invention se rapporte à une composition pharmaceutique contenant un dérivé de GLP-2 (peptide de type glucagon 2) ayant une solubilité et/ou une stabilité améliorée(s), ainsi qu'à un procédé permettant d'améliorer la solubilité et/ou la stabilité du peptide GLP-2 ou d'un fragment ou d'un analogue de ce peptide.
PCT/DK1999/000080 1998-02-27 1999-02-25 Derives de glp-2 avec teneur en structures en helices superieure a 25 %, formant des agregats de type micellaire partiellement structures WO1999043361A1 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
AU27128/99A AU2712899A (en) 1998-02-27 1999-02-25 Glp-2 derivatives with helix-content exceeding 25 percent, forming partially structured micellar-like aggregates
JP2000533156A JP2002504527A (ja) 1998-02-27 1999-02-25 部分的に組織化したミセル様凝集物を形成する２５％を越えるヘリックス成分を有するｇｌｐ−２誘導体
EP99907325A EP1060192A2 (fr) 1998-02-27 1999-02-25 Derives de glp-2 avec teneur en structures en helices superieure a 25 %, formant des agregats de type micellaire partiellement structures

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DK27198 1998-02-27
DK0271/98 1998-02-27

Publications (2)

Publication Number Publication Date
WO1999043361A1 true WO1999043361A1 (fr) 1999-09-02
WO1999043361A8 WO1999043361A8 (fr) 1999-10-14

Family

ID=8091669

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/DK1999/000080 WO1999043361A1 (fr) 1998-02-27 1999-02-25 Derives de glp-2 avec teneur en structures en helices superieure a 25 %, formant des agregats de type micellaire partiellement structures

Country Status (4)

Country Link
EP (1) EP1060192A2 (fr)
JP (1) JP2002504527A (fr)
AU (1) AU2712899A (fr)
WO (1) WO1999043361A1 (fr)

Cited By (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001049314A2 (fr) * 1999-12-30 2001-07-12 Nps Allelix Corp. Formulations de glp-2
WO2004035624A2 (fr) * 2002-10-14 2004-04-29 Novo Nordisk A/S Composes glp-2, leurs formulations et leurs utilisations
US6770620B2 (en) 2000-09-18 2004-08-03 Sanos Bioscience A/S Use of GLP for the treatment, prevention, diagnosis, and prognosis of bone-related and nutrition-related disorders
WO2004089985A1 (fr) * 2003-04-11 2004-10-21 Novo Nordisk A/S Compositions pharmaceutiques stables
WO2005027978A2 (fr) * 2003-09-19 2005-03-31 Novo Nordisk A/S Nouveaux derives de glp-1
WO2005028516A2 (fr) * 2003-09-19 2005-03-31 Novo Nordisk A/S Nouvelles etiquettes d'affinite pour les proteines plasmiques
WO2006097535A2 (fr) * 2005-03-18 2006-09-21 Novo Nordisk A/S Agonistes de peptides de la famille du glucagone presentant une activite similaire a la secretine
US7371721B2 (en) 2000-09-18 2008-05-13 Sanos Bioscience A/S Use of GLP-2 and related compounds for the treatment, prevention, diagnosis, and prognosis of bone-related disorders and calcium homeostasis related syndromes
CN100418983C (zh) * 2005-05-11 2008-09-17 中国药科大学 人胰高血糖素相关肽-2类似物
CN100444898C (zh) * 2003-09-19 2008-12-24 诺沃挪第克公司 治疗肽的清蛋白结合型衍生物
WO2009138488A1 (fr) 2008-05-15 2009-11-19 Novo Nordisk A/S Purification de peptides préparés par synthèse en phase solide
US7737251B2 (en) 2001-02-16 2010-06-15 Conjuchem Biotechnologies Inc. Long lasting glucagon-like peptide 2 (GLP-2) for the treatment of gastrointestinal diseases and disorders
EP2292253A2 (fr) 2003-06-03 2011-03-09 Novo Nordisk A/S Compositions pharmaceutiques stabilisées de peptides
EP2292254A2 (fr) 2003-06-03 2011-03-09 Novo Nordisk A/S Compositions pharmaceutiques stabilisées de peptide
US8513192B2 (en) 2009-01-22 2013-08-20 Novo Nordisk A/S Stable growth hormone compounds resistant to proteolytic degradation
US8536122B2 (en) 2005-03-18 2013-09-17 Novo Nordisk A/S Acylated GLP-1 compounds
US8603972B2 (en) 2005-03-18 2013-12-10 Novo Nordisk A/S Extended GLP-1 compounds
US8779109B2 (en) 2010-01-22 2014-07-15 Novo Nordisk Health Care Ag Growth hormones with prolonged in-vivo efficacy
US8841249B2 (en) 2009-08-06 2014-09-23 Novo Nordisk A/S Growth hormones with prolonged in-vivo efficacy
US8865868B2 (en) 2008-08-06 2014-10-21 Novo Nordisk Healthcare Ag Conjugated proteins with prolonged in vivo efficacy
US9060992B2 (en) 2004-11-01 2015-06-23 Nps Pharmaceuticals, Inc. Treatment of short bowel syndrome patients with colon-in-continuity
US9211342B2 (en) 2010-01-22 2015-12-15 Novo Nordisk Healthcare Ag Stable growth hormone compounds resistant to proteolytic degradation
US9364772B2 (en) 2003-04-08 2016-06-14 Novo Nordisk A/S Regeneration of chromatographic stationary phases
WO2019086559A1 (fr) 2017-10-31 2019-05-09 Adocia Composition comprenant un agoniste du recepteur du glp-2 et un co-polyaminoacide porteur de charges carboxylates et de radicaux hydrophobes
WO2020165900A1 (fr) 2019-02-11 2020-08-20 Opko Biologics Ltd. Analogues de glp-2 à action prolongée
US11045523B2 (en) 2013-04-05 2021-06-29 Novo Nordisk Healthcare Ag Formulation of growth hormone albumin-binder conjugate
WO2022157747A2 (fr) 2021-01-25 2022-07-28 Mylan Ireland Limited Compositions peptidiques pharmaceutiques et leurs procédés de préparation

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995007931A1 (fr) * 1993-09-17 1995-03-23 Novo Nordisk A/S Insuline acylee
WO1996032414A1 (fr) * 1995-04-14 1996-10-17 1149336 Ontario Inc. Peptide-2 analogue au glucagon et ses utilisations therapeutiques
WO1997031943A1 (fr) * 1996-03-01 1997-09-04 Novo Nordisk A/S Utilisation d'une composition pharmaceutique contenant un peptide visant a reduire l'appetit
WO1997039031A1 (fr) * 1996-04-12 1997-10-23 1149336 Ontario Inc. Analogues de peptide 2 du type glucagon
WO1998008872A1 (fr) * 1996-08-30 1998-03-05 Novo Nordisk A/S Derives de glp-2

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995007931A1 (fr) * 1993-09-17 1995-03-23 Novo Nordisk A/S Insuline acylee
WO1996032414A1 (fr) * 1995-04-14 1996-10-17 1149336 Ontario Inc. Peptide-2 analogue au glucagon et ses utilisations therapeutiques
WO1997031943A1 (fr) * 1996-03-01 1997-09-04 Novo Nordisk A/S Utilisation d'une composition pharmaceutique contenant un peptide visant a reduire l'appetit
WO1997039031A1 (fr) * 1996-04-12 1997-10-23 1149336 Ontario Inc. Analogues de peptide 2 du type glucagon
WO1998008872A1 (fr) * 1996-08-30 1998-03-05 Novo Nordisk A/S Derives de glp-2

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
PHARMACEUTICAL RESEARCH, Volume 15, No. 2, 1998, DEAN K. CLODFELTER et al., "Effects of Non-Covalent Self-Association on the Subcutaneous Absorption of a Therapeutic Peptide", pages 254-262. *

Cited By (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001049314A3 (fr) * 1999-12-30 2002-01-03 Nps Allelix Corp Formulations de glp-2
JP2003519195A (ja) * 1999-12-30 2003-06-17 エヌピーエス アレリックス コーポレーション Ｇｌｐ−２製剤
WO2001049314A2 (fr) * 1999-12-30 2001-07-12 Nps Allelix Corp. Formulations de glp-2
US7056886B2 (en) 1999-12-30 2006-06-06 Nps Allelix, Corp. GLP-2 formulations
JP5001498B2 (ja) * 1999-12-30 2012-08-15 エヌピーエス ファーマシューティカルズ インコーポレイテッド Ｇｌｐ−２製剤
JP2012116861A (ja) * 1999-12-30 2012-06-21 Nps Pharmaceuticals Inc Ｇｌｐ−２製剤
US7371721B2 (en) 2000-09-18 2008-05-13 Sanos Bioscience A/S Use of GLP-2 and related compounds for the treatment, prevention, diagnosis, and prognosis of bone-related disorders and calcium homeostasis related syndromes
US6770620B2 (en) 2000-09-18 2004-08-03 Sanos Bioscience A/S Use of GLP for the treatment, prevention, diagnosis, and prognosis of bone-related and nutrition-related disorders
US7737251B2 (en) 2001-02-16 2010-06-15 Conjuchem Biotechnologies Inc. Long lasting glucagon-like peptide 2 (GLP-2) for the treatment of gastrointestinal diseases and disorders
JP2010150276A (ja) * 2001-02-16 2010-07-08 Conjuchem Biotechnologies Inc 胃腸疾患および胃腸障害の処置のための長期持続性グルカゴン様ペプチド２（ｇｌｐ−２）
US7411039B2 (en) 2002-10-14 2008-08-12 Novo Nordisk A/S GLP-2 compounds, formulations, and uses thereof
WO2004035624A3 (fr) * 2002-10-14 2004-09-10 Novo Nordisk As Composes glp-2, leurs formulations et leurs utilisations
WO2004035624A2 (fr) * 2002-10-14 2004-04-29 Novo Nordisk A/S Composes glp-2, leurs formulations et leurs utilisations
US9364772B2 (en) 2003-04-08 2016-06-14 Novo Nordisk A/S Regeneration of chromatographic stationary phases
WO2004089985A1 (fr) * 2003-04-11 2004-10-21 Novo Nordisk A/S Compositions pharmaceutiques stables
US7595293B2 (en) 2003-04-11 2009-09-29 Novo Nordisk A/S Stable pharmaceutical compositions
EP2292253A2 (fr) 2003-06-03 2011-03-09 Novo Nordisk A/S Compositions pharmaceutiques stabilisées de peptides
EP2292254A2 (fr) 2003-06-03 2011-03-09 Novo Nordisk A/S Compositions pharmaceutiques stabilisées de peptide
WO2005028516A3 (fr) * 2003-09-19 2005-09-29 Novo Nordisk As Nouvelles etiquettes d'affinite pour les proteines plasmiques
EP2932981A3 (fr) * 2003-09-19 2016-02-24 Novo Nordisk A/S Nouveaux dérivés GLP-1 se liant à l'albumine
CN100444898C (zh) * 2003-09-19 2008-12-24 诺沃挪第克公司 治疗肽的清蛋白结合型衍生物
KR101241862B1 (ko) 2003-09-19 2013-03-13 노보 노르디스크 에이/에스 신규 ｇｌｐ-1 유도체
AU2004273573B2 (en) * 2003-09-19 2010-04-22 Novo Nordisk A/S Albumin-binding derivatives of therapeutic peptides
WO2005027978A3 (fr) * 2003-09-19 2005-05-19 Novo Nordisk As Nouveaux derives de glp-1
WO2005028516A2 (fr) * 2003-09-19 2005-03-31 Novo Nordisk A/S Nouvelles etiquettes d'affinite pour les proteines plasmiques
US7897560B2 (en) 2003-09-19 2011-03-01 Novo Nordisk A/S Plasma protein affinity tags
WO2005027978A2 (fr) * 2003-09-19 2005-03-31 Novo Nordisk A/S Nouveaux derives de glp-1
US9968657B2 (en) 2004-11-01 2018-05-15 Shire-Nps Pharmaceuticals, Inc. Treatment of short bowel syndrome patients with colon-in-continuity
US9545434B2 (en) 2004-11-01 2017-01-17 Nps Pharmaceuticals, Inc. Treatment of short bowel syndrome patients with colon-in-continuity
US9999656B2 (en) 2004-11-01 2018-06-19 Shire-Nps Pharmaceuticals, Inc. Treatment of short bowel syndrome patients with colon-in-continuity
US9993528B2 (en) 2004-11-01 2018-06-12 Shire-Nps Pharmaceuticals, Inc. Treatment of short bowel syndrome patients with colon-in-continuity
US9987334B2 (en) 2004-11-01 2018-06-05 Shire-Nps Pharmaceuticals, Inc. Treatment of short bowel syndrome patients with colon-in-continuity
US9987335B2 (en) 2004-11-01 2018-06-05 Shire-Nps Pharmaceuticals, Inc. Treatment of short bowel syndrome patients with colon-in-continuity
US9981014B2 (en) 2004-11-01 2018-05-29 Shire-Nps Pharmaceuticals, Inc. Treatment of short bowel syndrome patients with colon-in-continuity
US9981016B2 (en) 2004-11-01 2018-05-29 Shire-Nps Pharmaceuticals, Inc. Treatment of short bowel syndrome patients with colon-in-continuity
US9060992B2 (en) 2004-11-01 2015-06-23 Nps Pharmaceuticals, Inc. Treatment of short bowel syndrome patients with colon-in-continuity
US9981015B2 (en) 2004-11-01 2018-05-29 Shire-Nps Pharmaceuticals, Inc. Treatment of short bowel syndrome patients with colon-in-continuity
US9974838B2 (en) 2004-11-01 2018-05-22 Shire-Nps Pharmaceuticals, Inc. Treatment of short bowel syndrome patients with colon-in-continuity
US9974836B2 (en) 2004-11-01 2018-05-22 Shire-Nps Pharmaceuticals, Inc. Treatment of short bowel syndrome patients with colon-in-continuity
US9539310B1 (en) 2004-11-01 2017-01-10 Nps Pharmaceuticals, Inc. Treatment of short bowel syndrome patients with colon-in-continuity
US9968658B2 (en) 2004-11-01 2018-05-15 Shire-Nps Pharmaceuticals, Inc. Treatment of short bowel syndrome patients with colon-in-continuity
US9545435B1 (en) 2004-11-01 2017-01-17 Nps Pharmaceuticals, Inc. Treatment of short bowel syndrome patients with colon-in-continuity
US20170020971A1 (en) 2004-11-01 2017-01-26 Nps Pharmaceuticals, Inc. Treatment of short bowel syndrome patients with colon-in-continuity
US9555079B1 (en) 2004-11-01 2017-01-31 Nps Pharmaceuticals, Inc. Treatment of short bowel syndrome patients with colon-in-continuity
US20170028030A1 (en) 2004-11-01 2017-02-02 Nps Pharmaceuticals, Inc. Treatment of short bowel syndrome patients with colon-in-continuity
US9572867B2 (en) 2004-11-01 2017-02-21 Shire-Nps Pharmaceuticals, Inc. Treatment of short bowel syndrome patients with colon-in-continuity
US9592274B2 (en) 2004-11-01 2017-03-14 Shire-Nps Pharmaceuticals, Inc. Treatment of short bowel syndrome patients with colon-in-continuity
US9592273B2 (en) 2004-11-01 2017-03-14 Shire-Nps Pharmaceuticals, Inc. Treatment of short bowel syndrome patients with colon-in-continuity
US9974835B2 (en) 2004-11-01 2018-05-22 Shire-Nps Pharmaceuticals, Inc. Treatment of short bowel syndrome patients with colon-in-continuity
US9968656B2 (en) 2004-11-01 2018-05-15 Shire-Nps Pharmaceuticals, Inc. Treatment of short bowel syndrome patients with colon-in-continuity
US9968655B2 (en) 2004-11-01 2018-05-15 Shire-Nps Pharmaceuticals, Inc. Treatment of short bowel syndrome patients with colon-in-continuity
US9974837B2 (en) 2004-11-01 2018-05-22 Shire-Nps Pharmaceuticals, Inc. Treatment of short bowel syndrome patients with colon-in-continuity
WO2006097535A3 (fr) * 2005-03-18 2007-04-05 Novo Nordisk As Agonistes de peptides de la famille du glucagone presentant une activite similaire a la secretine
US8603972B2 (en) 2005-03-18 2013-12-10 Novo Nordisk A/S Extended GLP-1 compounds
WO2006097535A2 (fr) * 2005-03-18 2006-09-21 Novo Nordisk A/S Agonistes de peptides de la famille du glucagone presentant une activite similaire a la secretine
US8536122B2 (en) 2005-03-18 2013-09-17 Novo Nordisk A/S Acylated GLP-1 compounds
CN100418983C (zh) * 2005-05-11 2008-09-17 中国药科大学 人胰高血糖素相关肽-2类似物
WO2009138488A1 (fr) 2008-05-15 2009-11-19 Novo Nordisk A/S Purification de peptides préparés par synthèse en phase solide
US8865868B2 (en) 2008-08-06 2014-10-21 Novo Nordisk Healthcare Ag Conjugated proteins with prolonged in vivo efficacy
US8513192B2 (en) 2009-01-22 2013-08-20 Novo Nordisk A/S Stable growth hormone compounds resistant to proteolytic degradation
US8841249B2 (en) 2009-08-06 2014-09-23 Novo Nordisk A/S Growth hormones with prolonged in-vivo efficacy
US9211342B2 (en) 2010-01-22 2015-12-15 Novo Nordisk Healthcare Ag Stable growth hormone compounds resistant to proteolytic degradation
US8779109B2 (en) 2010-01-22 2014-07-15 Novo Nordisk Health Care Ag Growth hormones with prolonged in-vivo efficacy
US9695226B2 (en) 2010-01-22 2017-07-04 Novo Nordisk Healthcare Ag Growth hormones with prolonged in-vivo efficacy
US11045523B2 (en) 2013-04-05 2021-06-29 Novo Nordisk Healthcare Ag Formulation of growth hormone albumin-binder conjugate
WO2019086559A1 (fr) 2017-10-31 2019-05-09 Adocia Composition comprenant un agoniste du recepteur du glp-2 et un co-polyaminoacide porteur de charges carboxylates et de radicaux hydrophobes
WO2020165900A1 (fr) 2019-02-11 2020-08-20 Opko Biologics Ltd. Analogues de glp-2 à action prolongée
WO2022157747A2 (fr) 2021-01-25 2022-07-28 Mylan Ireland Limited Compositions peptidiques pharmaceutiques et leurs procédés de préparation
WO2022157747A3 (fr) * 2021-01-25 2022-09-01 Mylan Ireland Limited Compositions peptidiques pharmaceutiques et leurs procédés de préparation

Also Published As

Publication number Publication date
WO1999043361A8 (fr) 1999-10-14
EP1060192A2 (fr) 2000-12-20
JP2002504527A (ja) 2002-02-12
AU2712899A (en) 1999-09-15

Similar Documents

Publication Publication Date Title
WO1999043361A1 (fr) Derives de glp-2 avec teneur en structures en helices superieure a 25 %, formant des agregats de type micellaire partiellement structures
WO1998008872A1 (fr) Derives de glp-2
EP1062240B1 (fr) Derives de glp-1 modifies a l'extremite n-terminale
AU712096B2 (en) Lipophilic peptide hormone derivatives
EP3157949B1 (fr) Dérivés d'exendin-4 utilisés comme agonistes sélectifs du récepteur du glucagon
EP0894095B1 (fr) Derives de l'insuline et leur utilisation
EP2256129B1 (fr) Dérivés d'insuline
TWI547499B (zh) 胰高血糖素/glp-1受體協同激動劑
KR20060135661A (ko) 신규 ｇｌｐ-1 화합물
PL183698B1 (pl) Pochodna insuliny, kompozycja farmaceutyczna i zastosowanie pochodnej insuliny
JP2009530243A (ja) アシル化単鎖インスリン
US20080045450A1 (en) GLP-2 Derivatives
CN110845601A (zh) 不同构型的glp-1类似肽修饰二聚体及其制备方法在治疗ii型糖尿病中的应用
CN109248323B (zh) 酰化的glp-1衍生物
WO1998045329A1 (fr) Derives de peptides natriuretiques
US20020165148A1 (en) Analogues and derivatives of gastrin releasing peptide (GRP)

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

AK Designated states

Kind code of ref document: C1

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: C1

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WR Later publication of a revised version of an international search report
121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 1999907325

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: KR

WWP Wipo information: published in national office

Ref document number: 1999907325

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

NENP Non-entry into the national phase

Ref country code: CA

WWW Wipo information: withdrawn in national office

Ref document number: 1999907325

Country of ref document: EP